Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $48,024.50 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at $3,405,524.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Dyne Therapeutics Stock Up 0.5 %

Shares of NASDAQ DYN opened at $36.59 on Friday. The firm has a market cap of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07. The company’s fifty day simple moving average is $41.07 and its 200 day simple moving average is $33.61. Dyne Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on DYN shares. Piper Sandler raised their price objective on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Oppenheimer restated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Stifel Nicolaus upped their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new position in shares of Dyne Therapeutics during the first quarter valued at about $140,666,000. Janus Henderson Group PLC lifted its holdings in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after purchasing an additional 2,663,910 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $15,758,000. Price T Rowe Associates Inc. MD boosted its position in shares of Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock valued at $32,141,000 after buying an additional 1,118,590 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.